+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pemphigus Vulgaris (PV) - Epidemiology Forecast to 2030

  • ID: 5144516
  • Report
  • September 2020
  • Region: Global
  • 100 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2020
Pemphigus Vulgaris (PV) - Epidemiology Forecast to 2030 delivers an in-depth understanding of the PV, historical and forecasted epidemiology as well as the PV trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Pemphigus Vulgaris (PV) Disease Understanding

Pemphigus Vulgaris (PV) is defined as a potentially fatal, autoimmune and intraepithelial disease characterized by flaccid blisters, and erosions of the skin and mucous membrane. It is histologically marked by acantholysis and is mediated by circulating desmoglein-reactive autoantibodies, directed against keratinocyte cell surfaces.

PV is subdivided into two subtypes: mucosal-dominant type and mucocutaneous type. The mucosal-dominant type of PV shows blisters mainly and erosive lesions on the oral mucosa while mucocutaneous type also shows flaccid bullae and intractable erosions of the skin. PV is further segmented based on the severity of the disease as mild, moderate and severe.

Pemphigus Vulgaris (PV) Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of PV, Gender-specific Diagnosed Prevalent Population of PV, Severity-specific Diagnosed Prevalent Population of PV, and Age-specific Diagnosed Prevalent Population of PV scenario of PV in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Pemphigus Vulgaris (PV) Detailed Epidemiology Segmentation
  • The increasing geriatric population and rising prevalence of PV generates a large patient population in the 7MM. In 2017, the diagnosed prevalent population of PV in the 7MM was 41,217.
  • The United States contributes the largest share with 13,526 cases in 2017 acquiring near about 32.81% of the totals 7MM share. On the other hand, EU5 and Japan account for 60.10% and 7.09% diagnosed prevalent population share respectively in 2017.
  • A female predominance in PV is well established. However, the genetic and physiological basis for this gender bias is not well understood. In 2017, males and females contribute to 5,275 and 8,251 diagnosed prevalent cases in the US.
  • The epidemiology model for PV estimates that out of the total diagnosed prevalent population of 13,526 cases in the US for PV in 2017, 5,814 cases are of mild, 3,678 cases are of moderate, and 4,034 accounted for severe cases, respectively.
  • The majority of the PV cases were found in adults between 60-70 years of age. In 2017, 3,014 cases, 2,449 cases, were contributed by patients age 60-69 years, 70-79 years, and lowest cases observed in the age-group of 0-17 years (406 cases) in 2017, respectively in the US.
Scope of the Report
  • The report covers the descriptive overview of PV, explaining its causes, signs and symptoms, and pathophysiology.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of PV.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalent Population of PV, Gender-specific Diagnosed Prevalent Population of PV, Severity-specific Diagnosed Prevalent Population of PV, and Age-specific Diagnosed Prevalent Population of PV.
Report Highlights
  • 11-Year Forecast of PV
  • 7MM Coverage
  • Total Diagnosed Prevalent Population of PV
  • Gender-specific Diagnosed Prevalent Population of PV
  • Severity-specific Diagnosed Prevalent Population of PV
  • Age-specific Diagnosed Prevalent Population of PV
Key Questions Answered
  • What is the disease risk, burden and unmet needs of PV?
  • What is the historical PV patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of PV at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PV?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of PV during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Reasons to Buy

The PV report will allow the user to:
  • Develop business strategies by understanding the trends shaping and driving the 7MM PV epidemiology forecast.
  • The PV epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The proprietary PV epidemiology model is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030
Note: Product cover images may vary from those shown
1. Key Insights

2. Executive Summary of Pemphigus Vulgaris (PV)

3. Pemphigus Vulgaris (PV) Epidemiology Overview at a Glance
3.1. Epidemiology Share (%) Distribution of PV in 2017
3.2. Epidemiology Share (%) Distribution of PV in 2030

4. Disease Background and Overview: Pemphigus Vulgaris (PV)
4.1. Introduction
4.2. Clinical Manifestations
4.3. Disease Causes
4.4. Symptom of PV
4.5. Pathophysiology
4.6. PV Diagnosis
4.6.1. Diagnosis of Pemphigus Vulgaris: Recommendations by an International Panel of Experts
4.6.2. Pemphigus S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)

5. Case Reports
5.1. Nail disease in Pemphigus Vulgaris
5.2. Management of oral pemphigus vulgaris: A case report and a clinical update
5.3. Pemphigus Vulgaris and systemic lupus erythematosus in a 46 years old man
5.4. A case of concomitant pemphigus foliaceus and oral pemphigus vulgaris
5.5. A shift in clinical features, histologic findings and antigen profiles from Pemphigus Vulgaris to pemphigus foliaceus - two case studies

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. KOL Views
6.3. Epidemiology Methodology
6.4. Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the 7MM

7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the United States
7.3. Gender-specific Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the United States
7.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the United States
7.5. Severity-specific Diagnosed Prevalent Population of Pemphigus Vulgaris in the United States

8. EU5 Epidemiology
8.1. Germany Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Germany
8.1.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Germany
8.1.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Germany
8.1.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Germany
8.2. France Epidemiology
8.2.1. Assumptions and Rationale
8.2.2. Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in France
8.2.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in France
8.2.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in France
8.2.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in France
8.3. Italy Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Italy
8.3.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Italy
8.3.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Italy
8.3.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Italy
8.4. Spain Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Spain
8.4.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Spain
8.4.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Spain
8.4.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Spain
8.5. United Kingdom Epidemiology
8.5.1. Assumptions and Rationale
8.5.2. Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the UK
8.5.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the UK
8.5.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the United Kingdom
8.5.5. Severity-Specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in the United Kingdom

9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Japan
9.3. Gender-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Japan
9.4. Age-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Japan
9.5. Severity-specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Japan

10. Appendix

11. Bibliography
11.1. Report Methodology

12. Analyst Capabilities

13. Disclaimer

14. About the Publisher

List of Tables
Table 1 Summary of Pemphigus Vulgaris (PV), Epidemiology and Key Events (2017-2030)
Table 2 Drugs associated with PV
Table 3 Association of non-HLA genes with PV
Table 4 Differential diagnosis of oral lesions in PV
Table 5 PV diagnostic algorithm
Table 6 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the 7MM (2017-2030)
Table 7 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the US (2017-2030)
Table 8 Gender-specific Diagnosed Prevalence of PV in the US (2017-2030)
Table 9 Age-specific Diagnosed Prevalence of PV in the US (2017-2030)
Table 10 Severity-specific Diagnosed Prevalence of PV in the US (2017-2030)
Table 11 Total Diagnosed Prevalent Population of PV in Germany (2017-2030)
Table 12 Gender-Specific Diagnosed Prevalence of PV in Germany (2017-2030)
Table 13 Age-specific Diagnosed Prevalence of PV in Germany (2017-2030)
Table 14 Severity-specific Diagnosed Prevalence of PV in Germany (2017-2030)
Table 15 Diagnosed Prevalent Population of PV in France (2017-2030)
Table 16 Gender-specific Diagnosed Prevalence of PV in France (2017-2030)
Table 17 Age-specific Diagnosed Prevalence of PV in France (2017-2030)
Table 18 Severity-specific Diagnosed Prevalence of PV in France (2017-2030)
Table 19 Diagnosed Prevalent Population of PV in Italy (2017-2030)
Table 20 Gender-specific Diagnosed Prevalence of PV1 in Italy (2017-2030)
Table 21 Age-specific Diagnosed Prevalence of PV in Italy (2017-2030)
Table 22 Severity-specific Diagnosed Prevalence of PV in Italy (2017-2030)
Table 23 Diagnosed Prevalent Population of PV in Spain (2017-2030)
Table 24 Gender-specific Diagnosed Prevalence of PV in Spain (2017-2030)
Table 25 Age-specific Diagnosed Prevalence of PV in Spain (2017-2030)
Table 26 Severity-specific Diagnosed Prevalence of PV in Spain (2017-2030)
Table 27 Diagnosed Prevalence of PV in the UK (2017-2030)
Table 28 Gender-Specific Diagnosed Prevalence of PV in the UK (2017-2030)
Table 29 Age-specific Diagnosed Prevalence of PV in the UK (2017-2030)
Table 30 Severity-Specific Diagnosed Prevalence of PV in the United Kingdom (2017-2030)
Table 31 Diagnosed Prevalent Population of PV in Japan (2017-2030)
Table 32 Gender-specific Diagnosed Prevalence of PV in Japan (2017-2030)
Table 33 Age-specific Diagnosed Prevalence of PV in Japan (2017-2030)
Table 34 Severity-specific Diagnosed Prevalence of PV in Japan (2017-2030)

List of Figures
Figure 1 Typical features of a patient with PV
Figure 2 Clinical manifestations of Pemphigus
Figure 3 World map showing association of type II HLA genes with PV in different populations, grouped according to geographical regions
Figure 4 Pathogenesis of Pemphigus
Figure 5 Mechanisms of Acantholysis
Figure 6 B-cell and T-cell responses in Pemphigus
Figure 7 A multi-step approach for diagnosing PV
Figure 8 Pemphigus area and activity score
Figure 9 Pemphigus activity score
Figure 10 Pemphigus Disease Area Index
Figure 11 Pemphigus Vulgaris Lesion Severity Score
Figure 12 Harman’s Pemphigus Grading
Figure 13 Kumar’s Scoring system
Figure 14 Mahajan’s Scoring system
Figure 15 Diagnostic recommendations for PV by the International Panel of Experts
Figure 16 US KOL Views
Figure 17 Europe KOL Views
Figure 18 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the 7MM (2017-2030)
Figure 19 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in the US (2017-2030)
Figure 20 Gender-Specific Diagnosed Prevalence of PV in the US (2017-2030)
Figure 21 Age-specific Diagnosed Prevalence of PV in the US (2017-2030)
Figure 22 Severity-specific Diagnosed Prevalence of PV in the US (2017-2030)
Figure 23 Total Diagnosed Prevalent Population of Pemphigus Vulgaris (PV) in Germany (2017-2030)
Figure 24 Gender-Specific Diagnosed Prevalence of Pemphigus Vulgaris (PV) in Germany (2017-2030)
Figure 25 Age-specific Diagnosed Prevalence of PV in Germany (2017-2030)
Figure 26 Severity-specific Diagnosed Prevalence of PV in Germany (2017-2030)
Figure 27 Diagnosed Prevalent Population of PV in France (2017-2030)
Figure 28 Gender-specific Diagnosed Prevalence of PV in France (2017-2030)
Figure 29 Age-specific Diagnosed Prevalence of PV in France (2017-2030)
Figure 30 Severity-specific Diagnosed Prevalence of PV in France (2017-2030)
Figure 31 Diagnosed Prevalent Population of PV in Italy (2017-2030)
Figure 32 Gender-specific Diagnosed Prevalence of PV in Italy (2017-2030)
Figure 33 Age-specific Diagnosed Prevalence of PV in Italy (2017-2030)
Figure 34 Severity-specific Diagnosed Prevalence of PV in Italy (2017-2030)
Figure 35 Diagnosed Prevalent Population of PV in Spain (2017-2030)
Figure 36 Gender-specific Diagnosed Prevalence of PV in Spain (2017-2030)
Figure 37 Age-specific Diagnosed Prevalence of PV in Spain (2017-2030)
Figure 38 Severity-specific Diagnosed Prevalence of PV in Spain (2017-2030)
Figure 39 Diagnosed Prevalence of PV in the UK (2017-2030)
Figure 40 Gender-Specific Diagnosed Prevalence of PV in the UK (2017-2030)
Figure 41 Age-Specific Diagnosed Prevalence of PV in the UK (2017-2030)
Figure 42 Severity-specific Diagnosed Prevalence of PV in the United Kingdom (2017-2030)
Figure 43 Diagnosed Prevalent Population of PV in Japan (2017-2030)
Figure 44 Gender-specific Diagnosed Prevalence of PV in Japan (2017-2030)
Figure 45 Age-specific Diagnosed Prevalence of PV in Japan (2017-2030)
Figure 46 Severity-specific Diagnosed Prevalence of PV in Japan (2017-2030)
Note: Product cover images may vary from those shown
Adroll
adroll